Welcome

While we're waiting, please:

Rename yourself

1
Click the Participants icon

2
Hover over your name & click Rename

3
Add your name, pronouns and organization's name

4
Click OK

If you connected to the audio using your phone

- Find your participant ID; it should be at the top of your Zoom window
- Once you find your participant ID, press: #number# (e.g., #24321#)
- The following message should briefly pop-up: "You are now using your audio for your meeting"

Addiction Treatment Starts Here Learning Network

Kick Off Webinar

April 13, 2021

Housekeeping Reminders

Mute

Please mute when not speaking. Please don't put put the call on hold!

Chat Box

Use the chat box to introduce yourself and questions

Slides + Recording

Slides and recoding will be posted to the ATSH Online Home

Tech Issues

Private chat Briana or Meaghan for assistance

Contents

About the ATSH Learning Network

Getting to Know One Another

Learning Network Overview

Breakouts: StUD, virtual visits, and more

Next Steps

About the ATSH Learning Network

Addiction Treatment Starts Here: Core Team

Meaghan Copeland
Senior Program Coordinator
meaghan@careinnovations.org

Tammy Fisher
Vice President
tammy@careinnovations.org

Briana Harris-Mills
Senior Program Coordinator
brianna@careinnovations.org

Brian Hurley, MD
Addiction Physician and
General Psychiatrist, L.A.
County Dept. of Mental Health

ATSH Cohort At a Glance

- Learning Network cohort includes 16 teams, representing 12 organizations

- Teams are located across 9 different counties and include urban, suburban and rural sites

- Number of X-waivered prescribers:

  - 5 organizations have 1 – 5 clinicians

  - 5 organizations have 6 – 10 clinicians

  - 5 organizations have 11 – 24 clinicians

  - 1 organization > 100 clinicians

ATSH Cohort At a Glance

- Other Site Characteristics

 - All Learning Network participants have at least some patients receiving MAT:

    - Six organizations have 50 or fewer MAT patients

    - Four organizations serve between 50 – 100 patients

    - Six organizations serve more than 100 patients

  - About two-thirds of organizations indicated that they have some patients receiving treatment for Stimulant Use Disorder (StUD). Five participants have limited information on this patient population.

ATSH Cohort At a Glance

- Bartz Altadonna Community Health Center

- Bay Area Community Health

- County of Santa Cruz Health Services Agency

- El Dorado Community Health Center

- Family Health Centers of San Diego

- Livingston Community Health

- Los Angeles Christian Health Center – Joshua House Clinic

- Los Angeles Department of Health Services

- Salud Para La Gente

- School Health Clinics of Santa Clara County

- Valley Health Associates

- West County Health Centers

- Harbor – UCLA Medical Center Adult Primary Care
- Harbor – UCLA Medical Center Family Medicine
- Hubert H. Humphrey Comprehensive Health Center
- LAC + USC Medical Center
- Martin Luther King Jr. Outpatient Center

Getting to Know One Another

Getting to Know One Another

- Reflect on the last six months (since Sep 2020).
- What's **one challenge** your MAT team has faced?
- What's **one practice or change that's been impactful** for your MAT patients?

1 minute

7 minutes

- Find your team's circle on the Virtual Sticky Pad.
- Share your response to the reflection questions by "adding" two stickies.
- In the time left, peruse other teams' sticky notes by scrolling through the slides.

- In the chatbox, share one highlight from what you read during the "gallery walk"

5 minutes

Learning Network Overview

Learning Network Goal

Increase access to addiction treatment for opioid use disorder and stimulant use disorders, leveraging a peer group of 16 organizations, by focuses on learning, innovation and resilience

ATSH Learning Network Components

|		
Quarterly Webinars	**1**	90-minute webinars every quarter, organized around peer sharing on MAT program design and innovation
Coaching Office Hours	**2**	Office hours with ATSH coaches on a "drop-in" basis – offered either monthly or quarterly depending on demand
In-Person Learning	**3**	One *optional* in-person learning session (offered virtually if pandemic-related restrictions are still in place)
Site Visits	**4**	Apply to attend site visits with mature MAT programs (attendance will be limited)
Peer Forums	**5**	Access to peer forums for nurses, prescribers, behavioral health providers, and SUD counselors

Program Design

- MAT models for the future
- Refined care team roles
- Sustainable staff onboarding and orientation
- Improved patient ID through inreach/outreach

Whole-Person Care

- Trauma-informed care
- Use of stimulants and other substances
- Harm reduction
- Social risk factors
- Services to youth and pregnant patients

Culture Change

- Dig deeper into systemic bias and stigma
- Reduce disparities and improve health equity
- Care team resilience
- Integrate community perspective into design

Care Pathways

- Enhance linkages to community organizations
- Collaboration across care transition points
- Optimize partnerships with EDs, sobering centers, etc.

How is the Learning Network Different?

Refine and Enhance

Learning Network

- Optimize virtual care
- Explore health equity
- Trauma-informed
- Integrate lived experience
- Address social risk factors
- Focus on stimulant use disorder
- Care team roles for the future

Program Design
- MAT model
- Policies + procedures
- Care team roles

Training + Clinic Culture
- Engagement + buy-in
- Education + training

Care Delivery
- Patient identification
- Medication initiation
- Behavioral health

Care Coordination
- Clinical and non-clinical partners
- Referral pathways

Learning Collaboratives: Treating Addiction in Primary Care + Addiction Treatment Starts Here

MAT Building Blocks

Learning Network Expectations

Contribute	Receive
- Establish and participate as a core team of 2 – 4 individuals (should include project lead, clinical champion, and front line staff champion) - Actively engage in Learning Network activities, including all quarterly webinars - Commit to share best practices, challenges and lessons learned - Submit data at baseline and endpoint on program measure set for OUD and StUD measures.	- Free technical assistance from experts - Support from coaches to problem solve tough challenges - Platform to learn from peers about MAT program improvements - Access to forums and site visits to learn more from peers and high-performing sites - Centralized communications and resources

Measurement Strategy

Changes

Program Measure Set

- Collecting data at baseline and endpoint only, rather than quarterly
- Using a form instead of data portal
- Adjusted measures, including: revised OUD measures; adding measures related to stimulant use disorders

IMAT

- Optional for teams to complete; added modules related to trauma-informed care and equity

OUD Measures

- **Adoption:** Two sub measures, tracking prescribers (total and active)
- **Reach:** Four sub measures, tracking new and established patients receiving medications for OUD treatment
- **Retention:** Two sub measures, addressing continuation in care of new and established patients

StUD Measures

- **Identification:** Two sub measures, tracking patients identified with stimulant use disorder (StUD) and co-occurrence with OUD
- **Treatment:** Four sub measures, tracking patients receiving treatment for StUD, including medications, contingency management, and behavioral health interventions

Coming Up! Measurement Onboarding

Attend 1 onboarding webinar. Select <u>one</u> of these dates to attend:

- April 27, 12-1pm – <u>register here</u>

- May 4, 12-12:30pm – <u>register here</u>

Who should attend? The person(s) responsible for collecting and entering data at baseline/endpoint. We recommend that the team lead join in addition to any other data team member. **Baseline data is due on May 15, 2021.**

What will be covered? We will review the OUD and StUD measure set in detail and answer questions (e.g., how to pull accurate data). For those interested in the IMAT, we will introduce the two new modules and answer questions.

Key Dates – Measurement Strategy

Date/Deadline	Submission
April 27 OR May 4, 2021	Measurement Onboarding Webinar (attend 1 only)
May 15, 2021	Baseline program measure data (period 1/1/21 – 3/31/21) • Submit here: https://www.tfaforms.com/4893812 Optional: baseline IMAT • Submit here: https://www.tfaforms.com/4895412
January 14, 2022	Optional: midpoint IMAT
June 15, 2022	Optional: endpoint IMAT
July 15, 2022	Endpoint program measure data (period 4/1/22 – 6/30/22)

ATSH Online Home

Academy Dashboard   **Courses**   **Forums**   **Program Clubs**   Search... 🔍

Home > Clubs > ATSH Learning Network   🖾 Unread Content   ✔ Mark site read

ATSH Learning Network
Open Club · 11 members

Photo ▾

Welcome   ATSH Calendar   Activities & To-Do's   Data & Evaluation   Resource Library   Past Events   Program Roster   Members   Overview   Topics   Manage Club ▾

Welcome

Welcome to Addiction Treatment Starts Here's (ATSH) Virtual Home!

Thank you for being part of our community! This virtual home site is your one-stop shop for all things Addiction Treatment Starts Here. You can find information about upcoming

activities, reporting requirements, resources and more.

To get started, complete these tasks!

- Be sure to "Follow" this page! Click the blue button to bottom right of this page. You will be notified via email when there's a new update.
- Update your profile by clicking on your name in the top right hand corner, then click Profile. Once you're on your profile, click "Edit Profile" at the top right corner and add your pronouns and organization/affiliation and then click "Save".
- Explore the ATSH Virtual Home site! For any questions, please reach out to @Briana Harris-Mills

Navigation

- **Welcome:** Stay up-to- date with the most recent program information and news.
- **ATSH Calendar:** Access agendas and registration links for upcoming events.
- **Activities & To-Do's:** Access information about upcoming assignments.
- **Data & Evaluation:** Access templates and reporting due dates for quarterly data, capability assessments, and progress reports.
- **Resource Library:** We've got tons of resources to help you with your MAT program. Visit this tab to view resources and tools specific to MAT & OUD.
- **Past Events:** Access the recordings and slides of past ATSH events.
- **Program Roster:** Get in touch with others in our program! You can find contact information for program staff, coaches and project leads by organization.
- **Members:** See everyone who has joined the ATSH virtual home site. You can contact someone directly by clicking on their name.

ATSH Virtual Home on the CCI Academy

Create an account on the CCI Academy to join the ATSH Virtual Home. If you already have an account, log in.

Not a member yet?

Register here!

CCI
CENTER FOR CARE INNOVATIONS

Welcome, please login:

Username or E-mail

nikki@careinnovations.org

Password

•••••

☐ Remember Me

Log In

Forgot Password

What is the ATSH Virtual Home?

This virtual home will be your one-stop shop for all things Addiction Treatment Starts Here.

You will find information about upcoming activities, links to register for events, reporting requirements, MAT tools and resources and more!

ATSH Virtual Home Next Steps

1. Once logged in, **navigate to the Program Club tab** at the top of the page.

2. Find the ATSH Learning Network Page under the Featured Clubs section and **click the blue "Join Club" button**.

3. Once you've joined the club, **bookmark the website**!

Learning Network Topics

Group Discussion

- How can the Learning Network help?

  - What topics and technical assistance do you want the Learning Network to cover?

  - How might the Learning Network support resilience in your MAT care team and among your staff?

Stretch Break & Transition to Breakouts

Breakout Options

Most participants pre-registered for one of the following:

- Treating Stimulant Use Disorders (facilitated by Brian Hurley)

- Managing Virtual Care for MAT Patients (facilitated by Dominique McDowell)

- Integrating Contingency Management into MAT (facilitated by Katie Bell)

If you didn't pre-register, we selected a breakout for you. We will send you to your (virtual) breakouts during the stretch break.

Once we return from the breakouts, we will ask you two takeaways. In thinking about what to share, think about how this might impact your Learning Network experience (e.g., is there a challenge that came up that you'd like the Learning Network to schedule a webinar on)?

Stretch Break

Breakout Regroup

- Using the chat box, share your takeaways

- We also have a few minutes if you want to share out loud so please unmute yourselves!

Next Steps

Next Steps

- Continue to use the list serv for questions!

- Data onboarding webinar

- Baseline data due on May 15, 2021

- First quarterly webinar will be on July 27, 2021; topic is tbd

Poll Questions

1. On a scale of 1 – 5, please select the number that best represents your experience with today's session

   5 – Strongly Agree
   4 - Agree
   3 - Neutral
   2 - Disagree
   1 – Strongly Disagree

2. Please select the number that best represents your response to the statement: Today's session was a valuable use of my time.

   5 – Strongly Agree
   4 - Agree
   3 - Neutral
   2 - Disagree
   1 – Strongly Disagree

3. I can apply learnings from today's webinar to my MAT work.

   5 – Strongly Agree
   4 - Agree
   3 - Neutral
   2 - Disagree
   1 – Strongly Disagree

Thank you!

For questions contact:

Tammy Fisher
Vice President
Center for Care Innovations
tammy@careinnovations.org

Briana Harris Mills
Senior Program Coordinator
Center for Care Innovations
briana@careinnovations.org

CCI
CENTER FOR CARE
INNOVATIONS

Appendix: ATSH Measures

Program Measure Set Definitions

MEASURE	DEFINITION
A. **Adoption - Opioid Use Disorder (OUD)**	
A1 # of x-waivered prescribers	Total number of physicians, nurse practitioners or physician assistants, onsite and with whom the clinic site has contracts, who have obtained a Drug Addiction Treatment Act of 2000 (DATA) waiver to treat opioid use disorder (OUD) with medications approved by the U.S. Food and Drug Administration (FDA) for this indication. This number must be current up to the end of the reporting period, meaning that only x-waivered prescribers working at the site in the last month of the reporting period should be counted. Prescribers on leave or that left the organization during the last month of the reporting period would not be counted. Planned, in process or pending waivers do not count for the current reporting period.
A2 # of prescribers actively prescribing buprenorphine	Total number of prescribers who have prescribed buprenorphine for OUD to at least 1 patient during the reporting period. This measure does not apply to prescribers of naltrexone long-acting injection. Prescribers include those with and without an x-waiver.

Program Measure Set Definitions cont.

	MEASURE	DEFINITION
B.	**Reach - Opioid Use Disorder (OUD)**	
B1	# of patients prescribed buprenorphine	The total number of unique patients in the clinic site with a current, active prescription for any formulation of buprenorphine. Included patients may be new, restarted or established. "Active" is defined as having a current prescription during the last 30 days of the reporting period only**.**
		Do not count patients who were active earlier in the reporting period, but whose prescription expired prior to the last month of the reporting period.
		The buprenorphine medication should be FDA approved for the indication of OUD only. Excluded patients are those prescribed buprenorphine for indications that do not include OUD, such as pain.
B2	# of patients prescribed naltrexone long-acting injection	The total number of unique patients in the clinic site who were administered naltrexone long-acting injection during the last 30 days of the reporting period only**.** Included patients may be new, re-started or established.
		Do not count patients who were administered the injection earlier in the reporting period, but who did not receive the injection in the final month of the reporting period. Excluded patients are those prescribed naltrexone for alcohol use disorders.
B3	[Auto-calculated] Total # of patients prescribed/ administered medications for OUD	**No data is entered for this measure. The measure is automatically calculated as the sum of B1 and B2 entries for the current reporting period.**
		This measure represents the sum of new, restarted or established patients prescribed buprenorphine and administered naltrexone long-acting injection in the final 30 days of the reporting period.
B4	Total # of new or re-started patients prescribed/administered medications for OUD	Of the total number of patients calculated for B3, calculate the subset of patients who were newly started on the medications or who re-started medications during the last 30 days of the reporting period.

Program Measure Set Definitions cont.

MEASURE	DEFINITION
C. **Retention - Opioid Use Disorder (OUD)**	
C1 # of all patients prescribed medications for OUD (MOUD) 6 months prior to the reporting period who adhered continuously for 6 consecutive months	This measure is calculating the retention number and rate of all patients over a 6-month period. Tip: We recommend using a registry to track patients and make this calculation easier. Indicate when patients are newly started or re-started. The retention number is calculated by the numerator. The numerator is the total number of patients prescribed either buprenorphine or naltrexone long-acting injection for OUD at 6 months prior to the reporting date (equal to B3 from two quarters prior to the current reporting period), **and** who have remained in care continuously (without interruption) for 6 months. "Continuous care" is defined as patient care where gaps do not exceed 28 days. Care includes starting the medication, being prescribed refills and attending scheduled visits (in-person or virtual). The retention rate is calculated by dividing the numerator by the denominator. The denominator is all patients from 6 months prior (the same as B3 from two quarters prior to the current reporting period). The denominator is calculated automatically. **See full measure definitions document for example calculation.**
C2 # of new start or re-started patients prescribed MOUD 6 months prior to the reporting period who adhered continuously for 6 consecutive months	This measure calculates the retention of only new start or re-started patients over a 6-month period. This is a subset of patients calculated in Measure C1. Tip: We recommend using a registry to track patients and make this calculation easier. Indicate when patients are newly started or re-started to help with this measure's calculation. The retention number is calculated by the numerator. The numerator is the total number of patients started or re-started on buprenorphine or naltrexone long-acting injection for OUD at 6 months prior to the reporting date (equal to B4 from two quarters prior), **and** who have remained in care continuously and without interruption for 6 months. "Continuous" is defined as having no gaps in care of more than 28 days. Care includes starting the medication, being prescribed refills and attending clinic visits (in-person or virtual). The retention rate is calculated by dividing the numerator by a denominator that represents all new or re-started patients from 6 months prior (the same as B4 from two quarters prior). The denominator is calculated automatically.

Program Measure Set Definitions cont.

	MEASURE	DEFINITION
D.	**Identification - Stimulant Use Disorder (StUD)**	
D1	Total # of new patients identified as having an StUD	The total number of <u>new</u> patients at the clinic site identified within the reporting period with current ICD10 codes of one or more cocaine related disorders and/or stimulant related disorders or DSM5 diagnosis of a stimulant use disorder. A stimulant use disorder (StUD) is characterized by the disordered use of methamphetamine, cocaine, and/or other stimulants. "Current" is defined as within any of the 90 days of the reporting period. Patients with co-occurring substance use disorders (e.g., a patient with OUD and an StUD) may be counted. Guidance for identifying patients for this measure can be found in the full measurement definitions document.
D2	Total # of newly identified patients with an StUD who also have OUD	The total number of newly identified patients at the clinic site identified with a stimulant use disorder <u>who also</u> have a current ICD10 or DSM5 diagnosis of opioid use disorder. Use the population of patients you identified in D1. This measure calculates how many of these patients also have co-occurring OUD.

Program Measure Definitions cont.

MEASURE		DEFINITION
E.	**Treatment - Stimulant Use Disorder (StUD)**	
E1	Total # of newly identified patients with an StUD who received any treatment for an StUD	The total number of newly identified patients with a stimulant use disorder at the clinic site who received any documented treatment for an StUD on any date within the current reporting period. Treatment includes medications, contingency management, individual therapy, group therapy, other behavioral health interventions, or any other treatment. Use the population of patients you identified in D1. If a patient receives more than one form of treatment or received treatment multiple times during the reporting period, the patient should be counted only once for this measure.
E2	# of newly identified patients with an StUD who received medications for treatment of an StUD	The total number of newly identified patients with a stimulant use disorder at the clinic site who were administered any medication for the off-label indication of an StUD within the reporting period. Use the population of patients you identified in D1. Patients may be double counted across the different forms of treatment but not counted twice if medication was administered multiple times within the reporting period.
E3	# of newly identified patients with an StUD who received contingency management or other incentives as treatment for an StUD	The total number of newly identified patients with a stimulant use disorder at the clinic site who received contingency management or other incentives as treatment related to their StUD on any date within the current reporting period. Use the population of patients you identified in D1. Patients may be double counted across the different forms of treatment but not counted twice if they received this intervention multiple times within the reporting period.
E4	# of newly identified patients at your site with an StUD who received individual therapy, group therapy, or other behavioral health interventions as treatment for an StUD	The total number of newly identified patients with a stimulant use disorder at the clinic site who received any behavioral health intervention as treatment related to their StUD. Behavioral health interventions may include individual therapy, group therapy, or other interventions. Examples of interventions include cognitive behavioral therapy, community reinforcement approach, and motivational interviewing. Use the population of patients you identified in D1. Patients may be double counted across the different forms of treatment but not counted twice if they received this intervention multiple times within the reporting period.